(2R)-4-(Phenylmethyl)-2-morpholinemethanamine, 95.0%, 5g

2-Chloro-6,8-difluoroquinoline, 95.0%, 1g

2-Amino-N,N-dimethyl-benzamide, 98.0%, 25g

1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-one, 98%, 500mg

Tripropylene glycol monomethyl ether, min 97%, for synthesis, 1L, plastic packaging.

GC capillary column ROTI®Cap-FFAP, 30 m, 0.32 mm, 0.50 µm, 1 Piece(s)

(1S,4R,6S)-TERT-BUTYL 6-HYDROXY-2-AZABICYCLO[2.2.1]HEPTANE-2-CARBOXYLATE, 95.0%, 250mg

1-Methyl-4-(6-aminopyridin-3-yl)piperazine, 95.0%, 250mg

4-Bromo-2-chloro-5-(difluoromethyl)pyridine, 98%, 1g

2-Fluoro-4-iodopyridine, 98.0%, 10g

2-(1H-1,2,4-Triazol-1-yl)ethan-1-amine, 97%, 1g

Pyranine, 85%, 500g

5-Iodo-2-hydroxy-3-(trifluoromethyl)pyridine, 95.0%, 10g